Barclays Initiates Coverage of Senseonics Holdings at Equal-Weight
Fintel reports that on October 7, 2026, Barclays initiated coverage of Senseonics Holdings (NASDAQGS:SENS) (DB:6L60) with a Equal-Weight recommendation. This initiation follows a prior action on November 5, 2025, when the firm maintained an Overweight rating on the stock.
Senseonics Holdings, Inc., based in the United States, operates within the healthcare sector, specifically focusing on the development and commercialization of glucose monitoring systems for people with diabetes. The company's main product, the Eversense® Continuous Glucose Monitoring (CGM) system, is a long-term implantable device. This system allows for continual glucose monitoring, offering advantages in terms of convenience and efficiency compared to traditional CGM systems. The company's solutions align with their commitment to enhancing diabetic care management through advanced sensor technology and data integration capabilities.
On October 6, 2026, the pre-action close for the stock was $9.96, which matches the latest close of $9.96 on the same date. Over a one-week period, the stock experienced a price change of -0.90% from a baseline close of $10.05 on September 29, 2026. Over a one-month period, the price change was +3.43% from a baseline close of $9.63 on September 4, 2026.
In its latest earnings report on August 6, 2026, Senseonics reported an actual EPS of -0.63, compared to the estimated EPS of -0.6372. The company's actual revenue was $12,675,000.00, which compares to the estimated revenue of $13,128,420.00. The company's upcoming earnings date is scheduled for November 3, 2026.
Separately from Barclays' individual rating, the broader analyst consensus target mean was $14.48 as of October 2, 2026, with a median target of $15.30. This mean target represents an implied change of +45.42% from the stock's recent valuation. The prior consensus target mean was $13.67 as of September 15, 2026, reflecting a consensus target revision of +5.97%.
As of the current recommendation period starting September 1, 2026, the aggregate recommendation total stands at 13. This total includes 2 strong buy, 7 buy, 3 hold, 1 sell, and 0 strong sell recommendations, resulting in 69.2% positive, 23.1% hold, and 7.7% negative recommendations. These figures are identical to the prior recommendation period of August 1, 2026, which also recorded 13 total recommendations with the same distribution of 2 strong buy, 7 buy, 3 hold, 1 sell, and 0 strong sell ratings.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 7, 2026 | Barclays | Equal-Weight | initiated coverage |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.